Monitoring of KRAS mutation during cetuximab treatment of head and neck squamous cell carcinoma

Abstract

This work deals with the clinical relevance of KRAS mutation in head and neck squamous cell carcinomas. KRAS mutation was observed in a multicentre study during the search for predictive markers of the treatment by cetuximab and radiotherapy The results of the treatment in our patients were very good (80% compiete remission in locoregional advanced cancers), but the expected negative predictive effect of observed mutation was not demonstrated.

Keywords

• head and neck cancers
• KRAS mutations
• EGFR inhibitors
• cetuximab